Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KPL-387 transition to monotherapy in well-controlled recurrent pericarditis
2025-523234-66-00Phase 2Authorised
- Sponsor
- Kiniksa Pharmaceuticals
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 10
01
Overview
Phase 2, open-label, single-arm trial of KPL-387 in recurrent pericarditis, sponsored by Kiniksa Pharmaceuticals. Primary endpoints: Primary Efficacy Endpoint – Posology Period and Primary Efficacy Endpoint – LTE Period. Planned start Mar 2026; status: authorised.
02
Drugs
KPL-387
03
Conditions
recurrent pericarditis
Beyond the preview
Go deeper on 2025-523234-66-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523234-66-00.